Research ArticleHuman Studies
Pharmacokinetics and Normal Organ Dosimetry Following Intraperitoneal Rhenium-186-Labeled Monoclonal Antibody
Hazel B. Breitz, James S. Durham, Darrell R. Fisher, Paul L. Weiden, Gerald L. DeNardo, Henry M. Goodgold and Wil B. Nelp
Journal of Nuclear Medicine May 1995, 36 (5) 754-761;
Hazel B. Breitz
James S. Durham
Darrell R. Fisher
Paul L. Weiden
Gerald L. DeNardo
Henry M. Goodgold


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Pharmacokinetics and Normal Organ Dosimetry Following Intraperitoneal Rhenium-186-Labeled Monoclonal Antibody
Hazel B. Breitz, James S. Durham, Darrell R. Fisher, Paul L. Weiden, Gerald L. DeNardo, Henry M. Goodgold, Wil B. Nelp
Journal of Nuclear Medicine May 1995, 36 (5) 754-761;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study
- Phase I Study of 90Y-labeled B72.3 Intraperitoneal Administration in Patients with Ovarian Cancer: Effect of Dose and EDTA Coadministration on Pharmacokinetics and Toxicity